Citi opens ‘positive catalyst watch’ on Zimmer Biomet

Citi opened a “90-day positive catalyst watch” on shares of Zimmer Biomet (ZBH) while keeping a Neutral rating on the name with a $120 price target Zimmer has shown incremental improvements in defending its knee and hip market share, with both segments’ share becoming more stable year-over-year compared to the start of the year, the analyst tells investors in a research note. The firm says that given a “reasonable setup” into 2025 and an attractive valuation compared to peers, “some consistency is needed to get sentiment on track.”